38,043 Shares in Surmodics, Inc. (NASDAQ:SRDX) Bought by Mint Tower Capital Management B.V.

Mint Tower Capital Management B.V. purchased a new position in shares of Surmodics, Inc. (NASDAQ:SRDX) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 38,043 shares of the company’s stock, valued at approximately $1,507,000.

A number of other hedge funds have also bought and sold shares of SRDX. Modus Advisors LLC bought a new stake in Surmodics during the fourth quarter valued at approximately $40,000. Quest Partners LLC grew its holdings in shares of Surmodics by 107,100.0% in the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after purchasing an additional 1,071 shares during the last quarter. R Squared Ltd bought a new position in shares of Surmodics during the fourth quarter valued at about $55,000. SG Americas Securities LLC lifted its holdings in Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock worth $275,000 after buying an additional 1,255 shares during the period. Finally, Algert Global LLC boosted its holdings in Surmodics by 29.9% in the third quarter. Algert Global LLC now owns 17,820 shares of the company’s stock valued at $691,000 after acquiring an additional 4,098 shares in the last quarter. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SRDX has been the topic of a number of research analyst reports. StockNews.com assumed coverage on Surmodics in a report on Monday, February 3rd. They set a “hold” rating on the stock. Lake Street Capital upgraded shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Friday, March 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $50.00.

Surmodics Trading Down 1.4 %

Shares of SRDX stock opened at $30.48 on Thursday. The stock’s 50 day simple moving average is $33.11 and its two-hundred day simple moving average is $36.87. The company has a market cap of $435.74 million, a PE ratio of -30.18 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. Surmodics, Inc. has a 1 year low of $25.17 and a 1 year high of $42.44.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Research analysts predict that Surmodics, Inc. will post 0.2 earnings per share for the current year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).